Successful treatment of hypertension is possible with limited side effects given the
availability of multiple antihypertensive drug classes. This review describes the various …

JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses both hereditary
and acquired conditions. A systematic diagnostic approach begins with documentation of …

These guidelines cover the care of patients from the period following kidney transplantation
until the transplant is no longer working or the patient dies. During the early phase …

Disease Overview JAK2 unmutated or non‐polycythemia vera (PV) erythrocytosis
encompasses a heterogenous spectrum of hereditary and acquired entities. Diagnosis …

Background—Anemia is known to be a prognostic marker for patients with heart failure.
However, little is known about the prognostic value of changes in hemoglobin (Hgb) over …

Objectives: We aimed to investigate the impact of angiotensin-converting enzyme inhibitors
(ACEIs) on hematocrit values in those with heart failure, and the relationship between …

Background—Anemia is common in patients with chronic heart failure (CHF) and is
associated with a poor prognosis. However, only a minority of patients with CHF have …

More than a century has elapsed since the appearance of the modern descriptions of
polycythemia vera (PV). During this time, much has been learned regarding disease …

Erythrocytosis is an increase in the number of red blood cells. In a recent study from the
United States, the prevalence of primary erythrocytosis (known as polycythaemia vera) was …

In nontransplant populations, effects of different antihypertensive drug classes vary. Relative
effects in kidney transplant recipients are uncertain. We performed a systematic review …